WO2019045529A1 - Particules auto-assemblantes et procédé de préparation associé - Google Patents

Particules auto-assemblantes et procédé de préparation associé Download PDF

Info

Publication number
WO2019045529A1
WO2019045529A1 PCT/KR2018/010171 KR2018010171W WO2019045529A1 WO 2019045529 A1 WO2019045529 A1 WO 2019045529A1 KR 2018010171 W KR2018010171 W KR 2018010171W WO 2019045529 A1 WO2019045529 A1 WO 2019045529A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
polymer
antigen
particle
present
Prior art date
Application number
PCT/KR2018/010171
Other languages
English (en)
Korean (ko)
Inventor
함승주
김현욱
박근선
임종우
천해진
송대섭
나운성
염민주
Original Assignee
주식회사 휴벳바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 휴벳바이오 filed Critical 주식회사 휴벳바이오
Publication of WO2019045529A1 publication Critical patent/WO2019045529A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Definitions

  • the present invention relates to a self-assembled vaccine particle comprising a protein-amphipathic polymer and a method for producing the self-assembled vaccine particle.
  • the vaccine is injected with inactivated inactivated pathogenic agent or attenuated pathogenic agent which is weakly pathogenic in the human body prior to infection of the pathogenic organism, thereby activating the immune system of the human body, thereby allowing the immune cell of the human body to form an antibody, Even if they are infected, can prevent the disease caused by the pathogen or minimize the damage to prevent disease.
  • vaccines using inactivated or attenuated pathogens can cause hostility such as pain, redness, fever, chills, etc., and also cause infectious diseases in immunocompromised individuals.
  • purified pathogen components such as hemagglutinin (HA), a specific antigen of influenza virus, and surface antigen vaccine, purified from neuraminidase (NA), may be used .
  • HA hemagglutinin
  • NA neuraminidase
  • WO2011-151723 discloses a method of increasing the concentration of a vaccine antigen in a liquid composition.
  • a protein is present at a high concentration in a liquid composition state, There still exists a problem that the effect of the vaccine is inhibited by coagulation, degradation and the like.
  • the present invention is directed to solve the problem of low vaccine efficiency of a conventional virus vaccine, and it relates to an immunity inducing particle and a vaccine composition containing the immunity inducing particle which can efficiently induce an immune response by improving such efficiency.
  • the present invention also relates to a method for producing said immunostimulatory particles.
  • the present invention relates to an immunoinductive particle comprising a complex of an antigenic protein and an amphipathic polymer, which is formed by self-bonding of the antigenic protein-amphipathic polymer complex and comprises a hydrophobic polymer layer, a hydrophilic polymer layer, Inducing particle having a structure of an antigen protein layer.
  • the present invention also provides a vaccine composition comprising said immunostimulatory particles.
  • the present invention also provides a method for producing said immunostimulatory particles.
  • the immunogenic particles according to the present invention do not contain pathogens and contain only antigenic proteins, the density of the antigenic protein presented on the surface per particle is high and the immunity inducing effect is excellent and accompanied by side effects of the vaccine by the attenuated pathogen Moreover, it is possible to produce a simple and rapid production, making it possible to control an infectious disease such as a virus at an early stage.
  • 1A is a schematic view showing a process of synthesizing an amphipathic polymer according to an embodiment of the present invention.
  • FIG. 1B is a schematic view showing a vaccine particle by an antigen protein-amphipathic polymer self-assembly according to an embodiment of the present invention and particles bound with an antigenic protein on the surface of an amphipathic polymer.
  • Figures 2a, 2b and 2c are the results of confirming NMR peaks of synthesized materials synthesized according to one embodiment of the present invention.
  • FIG. 3A shows the results of confirming the peak change of the amphipathic polymer prepared according to an embodiment of the present invention with an FTIR analyzer.
  • FIG. 3B is a photomicrograph of nanoparticles prepared by varying the content of the hydrophobic polymer in the total mass of the amphipathic polymer according to an embodiment of the present invention.
  • FIGS. 4A and 4B are electron micrographs of immunoinducing particles prepared according to an embodiment of the present invention, and graphs illustrating the distribution of the average particle sizes of the immunoglobulin particles.
  • FIG. 4A and 4B are electron micrographs of immunoinducing particles prepared according to an embodiment of the present invention, and graphs illustrating the distribution of the average particle sizes of the immunoglobulin particles.
  • FIG. 5 is a microphotograph of immunostimulatory particles formed by self assembly of HA protein-amphipathic polymer complex prepared according to an embodiment of the present invention.
  • 6a and 6b are graphs showing the average particle diameter distribution of the immunity inducing particles according to the degree of modification produced according to an embodiment of the present invention: 6a the particle size according to the degree of modification of the albumin, 6b the hemagglutinin modification degree Size of self-assembled particles according to.
  • FIGS. 7A and 7B show the results of BCA analysis using the standard curve and the immunity inducing particle used in the BCA analysis using the immunity inducing particles according to an embodiment of the present invention.
  • FIG. 8 shows the result of confirming the immunity inducing ability in the mouse using the immunity inducing particles prepared according to one embodiment of the present invention.
  • Figure 9 shows the standard curve used for BCA analysis using immunostimulatory particles prepared according to one embodiment of the present invention.
  • FIG. 10 is a graph showing an antibody-induced response using OVA-immunoreactive particles prepared according to an embodiment of the present invention.
  • FIG. 11 shows the results of confirming the immune response inducing ability of the HA-immunoreactive particles prepared according to one embodiment of the present invention.
  • the present invention comprises a complex of an antigenic protein and an amphipathic polymer, wherein said complex provides self-assembled immunostimulatory particles.
  • Immunogen inducing particle in the present invention means a particle capable of inducing a humoral immune response or a cellular immune response by stimulating the immune system of an animal or a human within the host.
  • the immunostimulatory particles of the present invention induce an immune response in the host, thereby enabling rapid defense against the same antigen, preventing disease by the antigen or lowering the severity of symptoms.
  • the immunostimulatory particles of the present invention can be used as a vaccine and can be used interchangeably with vaccine particles.
  • the immunopotentiating particle of the present invention is formed by self-assembly of an antigen protein-amphipathic polymer complex, and the hydrophobic polymer layer, the hydrophilic polymer layer and the antigen Protein structure.
  • the antigen protein is formed at the outermost part of the particle. Since the antigen protein is contained in the immunoparticle in a state of being bound to the amphipathic polymer forming the self-assembled particle, a larger amount of the antigen protein And has an advantage in that the stability of the vaccine can be enhanced when the antigen protein is stably bound to the particles and is contained in a vaccine preparation or the like.
  • the immunostimulatory particle of the present invention contains only a specific antigen protein, the possibility of such side effect can be effectively solved.
  • the effect of the vaccine itself is too small.
  • the amount of antigen protein present on the surface of one immunoparticle can be significantly increased, An excellent effect can be recognized in that an excellent immune response can be induced in the administered subject.
  • a simple purified antigen protein and an immunostimulatory particle of the present invention were respectively injected into a mouse to induce an immune response, and the amount of the produced IgM antibody was confirmed. As a result, It was confirmed that it exhibited more excellent antibody forming effect when used.
  • the immunostimulatory particles of the present invention may further comprise a linker for linking the antigenic protein and the amphipathic polymer.
  • the antibody may further comprise a linker layer between the hydrophilic polymer layer and the antigen protein layer.
  • the linker layer allows a physically separated space between the antigenic protein and the amphipathic polymer to be secured in the immunity inducing particle, and the immunostimulating particle of the present invention has better particle stability due to the physical space.
  • the linker means a molecule having a reactive site at both ends so that two substances can be chemically synthesized and connected.
  • the linker of the present invention may be an amine linker molecule having an amine group or a linker molecule having a carboxyl group .
  • the amine linker molecule includes all diamine linker molecules having two amine groups (NH 2 ).
  • the diamine linker molecule is not limited to the type of the diamine linker molecule in that one end thereof reacts with the carboxyl group of the antigen protein and the other end thereof reacts with the amphipathic polymer to form an antigenic protein complex with the amphipathic polymer, .
  • linker molecule having a carboxyl group may have two carboxyl groups.
  • a linker-antigen protein bond can be formed by reacting with an amine group of an antigen protein.
  • the linker of the present invention can be selected from the group consisting of hexamethylenediamine, 1,4-diaminobutane, 1,8-diaminooctane, ethylenediamine, 1,6-hexanediamine 1,6-hexanediamine, phenylenediamine, 1,3-propanediamine, 1,13-tridecanediamine, 1,2-ethanediamine, 1,2-ethanediamine or 1,5-pentanediamine, but is not limited thereto.
  • the linker of the present invention may be hexamethylenediamine.
  • the immunogen inducing ability of the immunostimulatory particle of the present invention can be regulated by controlling the degree to which the antigen protein modifies the surface moiety with the linker.
  • degree of modification affects the antigenicity and stability of the immunostimulatory particles of the present invention, and when the conditions of the following formula 1 are satisfied, particles having a better immunostimulatory ability can be obtained.
  • the amount of the linker and the amount of the antigen protein in the formula 1 may be the amount of the linker and the antigen protein added to the reaction when the linker and the antigen protein are reacted to prepare the linker-antigen protein conjugate.
  • the immunostimulatory particles of the present invention may have a degree of modification according to the above formula 1 of less than 3, or less than 2. If the degree of modification is 3 or more, the antigenicity of the antigen protein bound to the particles may be lowered, and the immunity inducing effect may be lowered.
  • the degree of modification of the antigen protein in the immunostimulatory particle is 1/1000 or more to less than 2, or more than 1/500 to 1.8 or less than 1/100 or more to 1.7 or less, 1/80 or more to 1.6 or less , From 1/60 or more to 1.5 or less, from 1/40 or more to 1.4 or less, or from 1/20 or more to 1.3 or less, but is not limited thereto.
  • the antigenicity of the immunity inducing particle is excellent, and thus it has an excellent immune response inducing effect in the administration individual.
  • the antigen protein of the present invention may have a degree of modification of 1/1000 or more according to the above formula (1).
  • the degree of modification is less than 1/10, the binding between the amphipathic polymer and the antigen protein is reduced, and the hydrophobic interaction for self-assembly is reduced, which may lower the production efficiency of the immunity inducing particles.
  • the stability of the immunity inducing particle is lowered by the decrease of the hydrophobic interaction.
  • the amphipathic polymer means a particle having a region showing hydrophilicity and a region showing hydrophobicity.
  • the amphipathic polymer can be used without limitation as long as it is a particle having a hydrophilic region and a hydrophobic region.
  • the amphipathic polymer includes a hydrophilic polymer, a hydrophobic polymer, and a combination thereof.
  • the amphipathic polymer may be in the form of a polymer of a hydrophilic polymer and a hydrophobic polymer.
  • the amphiphilic polymer of the present invention may be in the form of (hydrophilic polymer) m- (hydrophobic polymer) n.
  • K may be an amphipathic polymer satisfying 0.1 to 0.8, or 0.2 to 0.6, or 0.3 to 0.5.
  • the stability of the immunity inducing particles is improved when the weight ratio is 0.1 to 0.6.
  • the amount of the hydrophobic polymer is too small, the hydrophobic interaction in the self-assembled particles may be weakened, and it is important that the above range is satisfied.
  • the hydrophilic polymer is a polyalkylene glycol (PAG), a polyacrylic acid (PAA), a polyacrylonitrile (PAN), a polyethylene oxide (PEO), a polyvinyl acetate (PVAc), a polyvinyl alcohol ), Polyvinylpyrrolidone, polyacrylamide, and hydrophilic polyamino acids, and derivatives thereof.
  • PAG polyalkylene glycol
  • PAA polyacrylic acid
  • PAN polyacrylonitrile
  • PEO polyethylene oxide
  • PVAc polyvinyl acetate
  • Polyvinylpyrrolidone Polyacrylamide
  • hydrophilic polyamino acids and derivatives thereof.
  • Such derivatives include, for example, (mono) methoxypolyethylene glycol, (mono) acetoxypolyethylene glycol, polyethylene glycol, copolymers of polyethylene and propylene glycol, polyvinylpyrrolidone, polyglutamine, polyglutamic acid, polythreonine, , Polyarginine, and polyserine.
  • the hydrophilic polymer may be methoxypolyethylene glycol (mPEG).
  • the hydrophobic polymer can be used without limitation as long as it is a substance capable of forming an amphipathic polymer together with a hydrophilic polymer.
  • the hydrophobic polymer may be at least one selected from the group consisting of polyesters, polyanhydrides, hydrophobic polyamino acids, polyorthoesters, and polyphosphazines.
  • the hydrophobic polyamino acid is selected from the group consisting of polylysine, polyisoleucine, polyvaline, polyphenylalanine, polyproline, polyglycine, polytryptophan, polyalanine, polylactide, polyglycolide, polycaprolactone, and polymethionine Or more.
  • the hydrophobic polymer includes a derivative thereof.
  • the amphipathic polymer of the present invention is a hydrophilic polymer comprising mPEG as a hydrophobic polymer and mPEG containing lactide (3,6-Dimethyl-1,4-dioxane-2,5-dione) and a polylactide copolymer (mPEG ) m- (b-PLA) n.
  • m may be 100 to 200
  • n may be 30 to 100.
  • antigen protein means a protein capable of inducing or promoting an immune response to an antigen, and includes fragments including an epitope region of the protein.
  • influenza viruses such as the hemagglutinin (HA), the neuraminidase (NA), the nucleoprotein (NP), the M1 protein, the M2 protein, the NS1 protein, the NS2 protein : Nuclear export protein), PA protein, PB1 protein (polymerase basic 1 protein), PB1-F2 protein and PB2 protein;
  • nuclear protein N
  • phosphorus protein P
  • substrate protein M
  • glycoprotein G
  • viral RNA polymerase L
  • Hepatitis B virus surface antigen (HBsAg), hepatitis B virus core antigen (HbcAg), hepatitis B virus DNA polymerase, HBx protein, preS2 middle surface protein, , Large S protein, viral protein VP1, viral protein VP2, viral protein VP3, and viral protein VP4;
  • the immunoinducing particle of the present invention induces an immune response in the form of nanoparticles bound to an amphipathic polymer, it is possible to induce a better immune response at a lower concentration than in the case where only an antigen protein is administered to induce an immune response. Therefore, the immunostimulatory particles of the present invention can be applied to any antigenic protein including a carboxyl group and an antigenic determinant site (epitope) capable of binding to the amphipathic polymer regardless of the type thereof, and thus the present invention is not limited to the kind of antigen protein .
  • the immunostimulatory particles of the present invention are self-assembled by an amphipathic polymer which is a constituent of the complex, that is, granulated by self-binding of an amphipathic polymer. Accordingly, the particles formed by the self-bonding of the present invention may include a polymer region (hydrophilic polymer layer, hydrophobic polymer layer) and an antigen protein region.
  • the self-assembled immunostimulatory particles of the present invention may have a membrane structure.
  • Membrane structure " in the present invention means a structure in which the inside is surrounded by a membrane or a shell.
  • the membrane structure may include a fluid or a separate configuration therein.
  • the membrane includes both a single membrane or a multi membrane having two or more single membranes.
  • a particle having a single membrane is again surrounded by a single membrane, it can be a particle having multiple membranes.
  • the single membrane and the multiple membrane are concepts that are distinguished from a single layer and a double layer.
  • a particle containing only one film of a bilayer structure has a single film
  • a particle including a film of a monolayer structure again surrounds a film of a single layer structure means a particle of a multi-film structure .
  • the nanoparticles having a membrane structure in the present invention may be vesicles, micelles, polymersome, droplets or colloidsome, but are not limited to, But are not limited to, rods, spheres, rings, plates, cylinders, ellipses, spheres, and the like.
  • the " micelle" means a particle having a hydrophobic core and a hydrophilic shell.
  • the micelle may be a polymer self-assembled micelle.
  • various forms can be adopted depending on the type of the polymer forming the copolymer, and the shape of the polymer is not limited thereto.
  • the micelle also includes a multi-layered form comprising two or more monolayers.
  • polymersome means a nanoparticle having a bilayer membrane structure having a " hydrophilic region-hydrophobic region-hydrophobic region-hydrophilic region ".
  • the polymer jars include both a single membrane of a bilayer membrane structure and multiple membranes containing two or more of the single membranes.
  • colloidal mule means a colloidal particle having a size of 1 nm to 1000 nm or a structure in which the granularity is packed tightly.
  • it may comprise a single layer and a bilayer.
  • the " droplet” means that the shape of the droplet in the film structure particles is represented by a droplet shape. Includes both single and double layers, and includes both single and multiple layers.
  • the self-binding form of the immunoadaginized particle of the present invention is more stable in the body than the vaccine of the single antigen protein type and can exhibit the antigen protein on the surface at a higher density than the conventional vaccine in which the antigen protein is bound to the nanoparticle Therefore, it is possible to induce an excellent immune response with an appropriate amount.
  • the present invention provides a vaccine composition comprising said immunostimulatory particles.
  • the present invention also provides a vaccine preparation comprising the immunostimulatory particles.
  • the vaccine composition of the present invention may further comprise at least one of a solvent, an adjuvant or an excipient in addition to the immunity inducing particle.
  • the immune enhancer may be Freund ' s incomplete or complete adjuvant, aluminum hydroxide gel, vegetable and mineral oil, etc.
  • the excipient include aluminum phosphate, aluminum But are not limited to, aluminum hydroxide or aluminum potassium sulfate (alum), and may further include any of the known materials used in the manufacture of vaccines well known to those skilled in the art.
  • the vaccine composition of the present invention may be prepared as an oral or parenteral preparation and may be prepared as an injectable solution in the form of a parenteral preparation and may be administered orally in the form of intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, But it is not limited to the mode of administration of the agent.
  • the present invention provides a method for producing said immunostimulatory particles.
  • the method for producing immunostimulatory particles of the present invention comprises mixing an amphipathic polymer and an antigen protein to form a complex; And self-binding and granulating the complex.
  • an antigenic protein-amphipathic polymer mixed solution to which an amphipathic polymer in a hydrophobic solvent is added to a protein solution containing an antigen protein in a hydrophilic solvent is reacted for 20 to 28 hours with shaking to form an amphipathic polymer-antigen protein complex To do; And a method in which the mixed solution is granulated by self-assembly of an amphipathic polymer-antigen protein complex when the hydrophobic solvent is a colloid phase in which the hydrophobic solvent exists in a droplet state in a hydrophilic solvent containing an antigenic protein.
  • the protein solution may further comprise glycerol.
  • glycerol it is very effective to prevent the antigen proteins in the composition from aggregating with each other and allow the protein to participate in the reaction more stably in the process of forming the antigen protein-amphipathic polymer complex.
  • the present invention relates to a method for preparing a protein solution, which comprises adding an amphipathic polymer in a hydrophobic solvent to a protein solution containing an antigen protein in a hydrophilic solvent and then shaking the mixture for a predetermined period of time or longer so that the hydrophobic solvent is dispersed in a hydrophilic solvent, , And the protein is characterized by being able to form particles formed in the outermost layers.
  • the hydrophobic polymer and the antigenic protein in the mixed solvent on the colloid phase may be in an interfacial state on different layers.
  • the production method of the present invention may further comprise modifying the antigen protein to a linker before the antigen protein-amphipathic polymer complex formation.
  • the complex is formed by modifying the protein with the linker, the possibility of contact between the moiety of the polymer and the moiety of the linker is increased, thereby increasing the efficiency of forming the antigen protein-amphipathic polymer complex.
  • the degree of modification can be calculated according to the formula 1 described in the description of the immunoinducing particle of the present invention, and the above contents are also applied to the present manufacturing method.
  • the immunostimulatory particles of the present invention can exhibit a strong immune response in a small amount by presenting an antigen protein in the form of nanoparticles irrespective of the kind of the antigenic protein, and thus have an excellent effect as a vaccine.
  • immune-inducing particles having an excellent immune reaction inducing effect can be produced without being limited to the kinds of antigen proteins, and thus they can be used variously in the field of vaccine production.
  • the invention provides a method of inducing an immune response in an individual comprising administering said immunity-inducing particle to a subject.
  • the method of inducing the immune response may be to prevent disease or infection in that it is intended to lower or prevent the possibility of infection of an individual with a disease.
  • the administration can be carried out more than once.
  • the method for inducing an immune response in an individual may be carried out by administering to a subject an amount of a pharmaceutically effective amount of a pharmaceutically effective amount to induce an immune response in the subject, thereby inducing humoral or cellular immunity response of the individual, Can reduce the likelihood of infection to the disease.
  • the pharmaceutically effective amount for inducing the immune response may be determined in consideration of physical conditions such as the specific form of the immunity inducing particle, the kind of the antigen protein, the age of the individual, and the body weight.
  • the immunoreactive particles of the present invention were administered to mice, and the blood of the mice was analyzed.
  • the production of IgM antibody against the antigen protein was effectively induced.
  • a larger amount of antibody is produced compared to a particle in which antigen is simply bound to the surface of the purified antigen protein or nanoparticle, and thus it can be used as a vaccine platform having a very high efficacy Respectively.
  • the amphipathic polymer to be bound to the antigen protein of the present invention can be prepared by reacting biocompatible polymer mPEG (Mw: 2,000) and lactide (3,6-dimethyl -1,4-dioxane-2,5-dione, Sigma Aldrich), and then an amphipathic polymer, mPEG-b-PLA, was synthesized through a ring opening reaction.
  • mPEC-b-PLA-COOH was prepared by replacing the OH group of mPEG-b-PLA with the COOH group in order to bind the above-mentioned copolymer and the antigen protein.
  • 500 mg of mPEG-b-PLA synthesized above, 80 mg of succinic anhydride (Sigma Aldrich) and 35.7 mg of DMAP (Sigma Aldrich) were placed in 10 mL of dichloromethane (DCM, Sigma Aldrich) ) was added dropwise. After reaction at ambient temperature for 24 hours, the resultant was precipitated with cold diethyl ether and vacuum dried to obtain mPEG-b-PLA-COOH.
  • MPEG-b-PLA-NHS was synthesized using NHS-sulfo as the mPEG-b-PLA-COOH synthesized above. Specifically, 325 mg of mPEG-b-COOH synthesized above, 17 mg of NHS (Thermo Scientific) and 21 mg of DCC (Sigma Aldrich) were placed in 10 mL of dichloromethane (DCM, Sigma Aldrich), and 20 ⁇ L of triethylamine Drop method. The reaction was allowed to proceed at ambient temperature for 24 hours. The resultant was precipitated with cold diethyl ether and vacuum dried to obtain mPEG-b-PLA-NHS.
  • NHS Thermo Scientific
  • DCC dichloromethane
  • DCM dichloromethane
  • NMR was used to confirm the synthesis of each step of the copolymer synthesized by NMR. As shown in FIGS. 2A, 2B, and 2C, peaks of PLA and PEG are common and a peak of each functional group is observed.
  • (mPEG) m- (b-PLA) n was synthesized by varying polymerization ratios of mPEG and lactide (3,6-Dimethyl-1,4-dioxane-2,5-dione) .
  • the amounts of mPEG and lactide (3,6-Dimethyl-1,4-dioxane-2,5-dione) were adjusted as shown in Table 1 below.
  • the FTIR analysis results confirmed that the peak of the C-H moiety decreased as the moiety of mPEG decreased in the copolymer.
  • (MPEG) m- (b-PLA) was obtained by varying the polymerization ratios of mPEG and lactide (3,6-Dimethyl-1,4-dioxane-2,5- ) n were synthesized and the morphological characteristics of the self - assembled particles were confirmed according to the proportion of the hydrophilic polymer.
  • the shape of the self-assembled particles produced varies depending on the weight ratio of the hydrophilic polymer in the amphipathic polymer.
  • the ratio (f) of the hydrophilic polymer is 0.05% by weight, there is a problem that the shape of the rod is formed but the stability of the shape of the particle is unstable.
  • the immunoinducing particle of the present invention is characterized in that it is a particle formed by self-assembly of an antigen protein-amphipathic polymer complex.
  • the antigen protein In order to have immunity-inducing ability, the antigen protein must be located at the outermost position of self-assembly.
  • the self-assembled particles having the antigen protein of the present invention at the outermost periphery were prepared by the following method.
  • antigenic proteins ovalbumin (Thermo Scientific) and hemagglutinin (A / California / 04/2009 (H1N1), SEQ ID NO: 1) were used.
  • the antigen protein and hexamethylenediamine (linker) were reacted to modify the antigen protein with the linker.
  • 5 vol% glycerol was added to the OVA (1 mg / 1 mL) solution.
  • To the 300 ⁇ l of the OVA (1 mg / 1 ml) solution was added 40 ⁇ l of EDAC / Sulfo-NHS solution (20 mg each of 100 ⁇ l of DW), and 80 ⁇ l of hexamethylenediamine (104 mg / DW 2 ml) was added to the mixture.
  • the amphipathic polymer - antigen protein complex was interfaced with the hydrophilic solvent between the chloroform droplet and the hydrophilic solvent and self - assembled and granulated.
  • the hydrophobic polymer in the chloroform droplet forms the inside of the particle, and the hydrophilic polymer is formed on the hydrophobic polymer layer by the interaction of the hydrophobic polymer, and the antigen protein is formed on the outermost layer of the particle by the linker.
  • self-assembled particles (proteSome) of mPEG-b-PLA-OVA complex were obtained.
  • the mPEB-b-PLA-HA complex was formed and granulated in the same manner as above to obtain self-assembled particles of mPEB-b-PLA-HA complex.
  • the granulation degree of the mPEG-b-PLA-OVA complex and the mPEB-b-PLA-HA complex was confirmed using DLS and electron microscope, and the particle size was measured.
  • the degree of surface modification of the protein antigen is related to the antigenicity of the protein and the stability of the vaccine, experiments were carried out to confirm the antigenicity by varying the degree of protein modification by the linker hexamethylenediamine (Hexa.).
  • the OVA protein 45 kDa was used as a stock solution (OVA 1 ⁇ g / ⁇ l) and the amphipathic polymer mPEG-b-PLA-NHS (molecular weight 6 kDa) synthesized in Preparation Example 1 was used.
  • Modification ratio when said amount (mg) a modified constant (k) of the linker required to modify the antigenic proteins 1mg, represents a (x k amount of antigen) the value of the amount of linker /.
  • the amount of hexamethylenediamine (unit molar mass: 116.21 g / mol) required to modify 1 mg of OVA protein was 11.5 mg.
  • the amount of hexamethylenediamine required to modify 1 mg of hemaglutinin was 6.088 mg.
  • the hydrodynamic diameter was measured to be about 500 nm, and a tendency was shown that the size variation occurred as the modification ratio was lowered.
  • the surface of the nanoparticles In order to confirm the difference in effect as a vaccine for particles in which the antigen protein is bound to the surface of the self-assembled particles of the antigenic protein-amphipathic polymer complex of the present invention and the polymer, the surface of the nanoparticles .
  • the antigen protein (OVA, HA) was modified to 1/10 of the degree of modification and then granulated in the self-assembled form using the amphipathic polymer mPEG-b-PLA-NHS (molecular weight 6 kDa). Then, the EDC / Sulfo-NHS stock was added and antigen protein OVA (45 kDA) was added to prepare OVA-surface-bound nanoparticles (Comparative Example 2) by mixing the self-assembled nanoparticles with the OVA protein. The HA protein was also treated in the same manner as above to prepare HA-surface-bound nanoparticles (Comparative Example 3). The amount of the antigen protein used and the amount of the reactant were prepared in the same manner as in the case of the modification degree 1/10 in Table 4.
  • the experiment was divided into the group treated with OVA only (positive control group), the group treated with the immunity inducing particles of the present invention (Examples 1, 2, 3 and 4) and the group treated with nothing (negative control) .
  • the immunostimulatory particle treatment group modification of the antigen protein by hexamethylenediamine was started from the modification 1 of Example 1, and each of the prepared immunostimulatory particles was reduced by 1/2.
  • Immunoreactive particles were inoculated by BCA analysis after the quantitative control. Specifically, they were quantitated by a reliable standard curve (Fig. 7a) with R 2 ⁇ 0.99 and analyzed both before and after the first inoculation and the second inoculation To control the density. However, in the case of the first injection group of Example 2, the first dose was carried out at a low concentration because the production amount of the nanoparticles was small.
  • the contents of the specifically inoculated vaccines are shown in Table 5 below.
  • Immunoreactive particles were inoculated after BCA analysis and after controlling the density. Specifically, they were quantitated with a reliable standard curve (Fig. 9) at 2 ⁇ 0.99 and analyzed both before and after the first inoculation and the second inoculation To control the density. The contents of the specifically inoculated vaccines are shown in Table 6 below.
  • OVA mPEG-b-PLA-NHS ( ⁇ ⁇ / 50 ⁇ ⁇ ) Primary vaccination (/ / 50)) Second inoculation (/ / 50)) Comparative Example 1 (OVA alone) X 20 20 Example 6 334 20 20 Example 7 334 20 20 Example 8 334 20 20 Comparative Example 2 (Surface Bonded Particle) 334 20 20 Negative control 2 X X X
  • blood collection was carried out (primary blood collection after inoculation) and the second vaccination was inoculated.
  • second blood collection after inoculation was carried out.
  • the degree of antibody (IgG) induction by enzyme immunoassay (ELISA) was determined by measuring the absorbance intensity of the serum of the blood obtained by the primary blood collection and the secondary blood collection after inoculation.
  • the absorption intensity of each experimental group is shown in Table 7.
  • the self-assembled antigen particles of Examples 6 to 8 of the present invention exhibit high antibody-inducing ability as compared to antigen particles or protein alone bound to the surface of the amphipathic particles, so that they can be used as an effective vaccine platform as compared with conventional vaccine preparations This is possible.
  • N 5 HA P (Comparative Example 3) HA 1 (Example 9) HA 0.1 (Example 10) HA 0.01 (Example 11) NC (negative control group 3) Average 0.84721 1.28734 2.3174 1.49575 0.0735 STD 0.224198 0.291706 0.331991 0.128784 0.003486

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des particules immuno-dirigées dans lesquelles un polymère macromoléculaire amphipathique à protéine antigénique est auto-assemblé, l'induction d'un plus grand nombre de réponses immunitaires même avec une quantité plus petite de vaccin étant possible lors de l'utilisation des particules immuno-dirigées de la présente invention comparé à un vaccin classique qui contient simplement une protéine antigénique dans un vecteur. L'invention concerne également une plateforme de vaccin efficace, les effets secondaires tels que des infections de maladies virales pouvant être éliminés.
PCT/KR2018/010171 2017-08-31 2018-08-31 Particules auto-assemblantes et procédé de préparation associé WO2019045529A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0111104 2017-08-31
KR20170111104 2017-08-31

Publications (1)

Publication Number Publication Date
WO2019045529A1 true WO2019045529A1 (fr) 2019-03-07

Family

ID=65527802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/010171 WO2019045529A1 (fr) 2017-08-31 2018-08-31 Particules auto-assemblantes et procédé de préparation associé

Country Status (2)

Country Link
KR (1) KR20190024849A (fr)
WO (1) WO2019045529A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113264997A (zh) * 2021-04-13 2021-08-17 康汉医药(广州)有限公司 一种蛋白药物在常温、高温条件下保存的方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023500921A (ja) * 2019-11-07 2023-01-11 サムヤン ホールディングス コーポレイション 免疫誘導用ポリマーナノ粒子組成物及びその製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140117249A (ko) * 2013-03-22 2014-10-07 부산대학교 산학협력단 단백질 케이지의 제조방법 및 소수성 첨가제를 담지한 코어-쉘 구조의 고분자-단백질 입자의 in-situ 제조방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140117249A (ko) * 2013-03-22 2014-10-07 부산대학교 산학협력단 단백질 케이지의 제조방법 및 소수성 첨가제를 담지한 코어-쉘 구조의 고분자-단백질 입자의 in-situ 제조방법

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKAGI, T.: "Preparation of nanoparticles by the self-organization of polymers consisting of hydrophobic and hydrophilic segments: Potential applications", POLYMER, vol. 48, no. 23, 2007, pages 6729 - 6747, XP022313433 *
GU, F.: "Precise engineering of targeted nanoparticles by using self- assembled biointegrated block copolymers", PNAS, vol. 105, no. 7, 2008, pages 2586 - 2591, XP055001320, DOI: doi:10.1073/pnas.0711714105 *
SAPSFORD, K. E.: "Functionalizing Nanoparticles with Biological Molecules: Developing Chemistries that Facilitate Nanotechnology", CHEMICAL REVIEWS, vol. 113, no. 3, 2008, pages 1904 - 2074, XP055280274 *
VALENCIA, P. M.: "Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticle s", BIOMATERIALS, 2011, pages 6226 - 6233, XP028097278, DOI: doi:10.1016/j.biomaterials.2011.04.078 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113264997A (zh) * 2021-04-13 2021-08-17 康汉医药(广州)有限公司 一种蛋白药物在常温、高温条件下保存的方法

Also Published As

Publication number Publication date
KR20190024849A (ko) 2019-03-08

Similar Documents

Publication Publication Date Title
Jain et al. PEG–PLA–PEG block copolymeric nanoparticles for oral immunization against hepatitis B
CN1134265C (zh) 用作为免疫佐剂的磷腈聚电解质
EP0762875B1 (fr) Systeme de liberation de microparticules
EP0245078B1 (fr) Augmentation de l'immunogénicité d'antigènes
Lamalle-Bernard et al. Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity
US6562352B1 (en) Vaccine compositions for mucosal delivery
US6541000B1 (en) Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
JP4743928B2 (ja) 処方物
JP2010265330A6 (ja) 処方物
WO2010151076A2 (fr) Composition adjuvante comportant des nanoparticules de (poly-gamma-glutamate)-chitosane
JP2002540076A (ja) ワクチン組成物
JP6228967B2 (ja) 抗原性組成物および方法
CN1128953A (zh) 水凝胶微囊包封的疫苗
WO2019045529A1 (fr) Particules auto-assemblantes et procédé de préparation associé
US4567041A (en) Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
HU176180B (en) Process for preparing antigenic compositions
US8853354B2 (en) Polyion complex comprising hydrophobized polyamino acid and use of the same
KR20170072157A (ko) 스쿠알렌을 포함하는 양친매성 폴리 아미노산 고분자 기반 백신 면역보조제 조성물
AU2001269640B2 (en) Vaccine against the influenza virus and method for producing said virus vaccine
KR102643430B1 (ko) pH 감응형 나노 복합체를 활용한 백신 전달체
CN107823185B (zh) 一种以复合纳米材料为载体的口服给药系统
KR19980067137A (ko) 알긴산염 초미세과립구를 이용한 폐렴구균 감연중에 대한 백신
CN114805602B (zh) 一种用于结合IgE的多肽纳米材料及其制备方法和应用
CN108096571B (zh) 一种用于防治结核病的结核多肽疫苗及其制备方法、应用
WO2017191646A2 (fr) Nanoformulation d'alginate-chitosane de la sous-unité de protéine ompa-a de shigella

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18852419

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18852419

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 18852419

Country of ref document: EP

Kind code of ref document: A1